Yesterday the DPH released updated guidance on Caring for LTC Residents during the COVID-19 Emergency which required testing of all staff that were not up to date with COVID-19 vaccine at the beginning of each shift, and on Friday, January 21, 2022, the FDA approved Remdesivir (Veklury), administered in a series of three daily intravenous infusions (200 mg, 100 mg, 100 mg), for patients not hospitalized due to COVID-19 and with mild-to-moderate COVID-19 within seven days of symptom onset in patients at risk of progression to severe disease.
Read more